ClinicalTrials.gg
Not yet recruitingNCT07634510Updated Jun 10, 2026

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205

A Phase 1 interventional study of MWX205 and Placebo in Dyslipidemias, sponsored by Shanghai Minwei Biotechnology Co., Ltd. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Shanghai Minwei Biotechnology Co., Ltd (part of Lepu Medical) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study is being done to test a new injection called MWX205 in people with high cholesterol or fat levels in the blood (dyslipidemia).

Researchers will check if a single dose of MWX205 is safe and how the body reacts to it. They will also measure how quickly the drug enters the bloodstream and how long it stays in the body, and compare it with a placebo (inactive treatment).

The study will help decide the right dose and understand how this medicine could be used in future treatments.

The main questions this study aims to answer are:

  1. Is MWX205 safe after a single dose?
  2. How does the body process MWX205?
  3. Does MWX205 show any effect on the body related to cholesterol levels?
Read the detailed description

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of MWX205 Injection will be assessed in adult participants with dyslipidemia.

Overall, 37 participants will be enrolled and assigned to 5 sequential cohorts (Cohorts 1 through 5).

Cohort 1 will enroll 5 participants and be randomized 3:2 to receive a single dose of MWX205 or placebo (3 participants receiving MWX205 and 2 receiving a placebo).

Cohorts 2 to 5 will be comprised of 8 participants per Cohort and randomized 3:1 to receive a single dose of MWX205 or placebo, respectively (6 participants receiving MWX205 Injection and 2 receiving a placebo).

Dosing in each cohort will be such that 2 participants (1 MWX205 Injection and 1 placebo) will be administered at least 24 hours before the remaining 3 participants (the first cohort) or 6 participants (cohorts 2-5). After dosing the first 2 participants on a separate day, a minimum of a 5-minute dosing interval for the remaining 3 participants (the first cohort), or 6 participants (cohorts 2-5) in the following cohort, is considered acceptable.

Continuation to dose the remaining 3 participants (Cohort 1) or 6 participants (Cohorts 2-5) will be at the investigator's discretion.

Each participant will participate in 1 cohort only, residing at the Clinical Research Unit (CRU) from Day -1 (the day before dosing) to Day 8.

02

Conditions studied

  • Dyslipidemias

Browse trials for

03

In context

Dyslipidemias

1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

This study's planned enrollment of 37 is below the median of 100 across 987 interventional studies indexed under Dyslipidemias.

Browse Dyslipidemias studies →

Lead sponsor

Shanghai Minwei Biotechnology Co., Ltd is the lead sponsor of 21 studies on the registry; 10 are open to participants now.

First submitted after Shanghai Minwei Biotechnology Co., Ltd became part of Lepu Medical.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult participants with dyslipidemia will be enrolled in this study.
  2. The absence of illness and surgery within 4 weeks prior to study drug administration.
  3. Participants must have fasting triglycerides greater than or equal to 150 mg/dL (1.7 mmol/L) and less than 500 mg/dL (5.7 mmol/L), and LDL-C greater than or equal to 70 mg/dL (1.8 mmol/L) at pre-screening and confirmation within 7 days before randomization.
  4. Have a within the range 18.5 to 40.0 kg/m2 (inclusive), with no plans to significantly alter diet or BMI over the course of study.
  5. Females of and males who are not surgically sterile (> 90 days since vasectomy with no viable sperm) will agree to use from Screening until 6 months after the administration, OR females of non-

Exclusion criteria

Exclusion Criteria:

  1. Positive pregnancy test or lactating female participant.
  2. Systolic BP lower than 90 or over 140 mmHg, diastolic BP lower than 40 or over 90 mmHg, HR less than 40 or over 100 bpm at screening.
  3. over 450 ms at screening.
  4. Consume more than 7 units for women or 14 units for men of alcohol per week within 8 weeks prior to screening (1 unit = 285 mL of beer 3.5%, 75 mL of wine 13.5%, or 25 mL of distilled alcohol 40%).
  5. Participants with established coronary artery disease, peripheral arterial disease, prior stroke, or other atherosclerotic cardiovascular disease (such as stent placement or heart bypass, unstable angina or last known of \<50%).
  6. History of intolerance to SC injection or relevant abdominal scarring (surgical, burns, etc.), or any skin conditions, including infections or open wounds, or dermatitis at the injection site that could interfere with the evaluation of injection reaction.
  7. Have taken any prescription medications that are specifically indicated for lowering serum TGs (e.g., fibric acid derivatives, niacin, and omega-3 fatty acids [>1 g/day]) or medications that interfere with absorption of dietary cholesterol or fats (e.g., bile acid sequestrants, orlistat) within 2 months prior to screening.
  8. Have received treatment with any liver-targeted siRNA therapy or ASO (Antisense Oligonucleotide) within12 months prior to screening.
  9. Use of ANGPTL3 or PCSK9-inhibiting monoclonal antibodies within 90 days prior to screening.
  10. Use of systemic therapy for more than 14 consecutive days in the past year, or any glucocorticoid therapy (excluding topical, intra-ocular, intra-articular, intranasal, or inhaled preparations) within 1 month before screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    MWX205

    Strength: 1ml: 200 mg Proposed dose levels for SAD study: 50, 200, 400, 800, and 1200 mg Administration: subcutaneous injection, recommended in the abdomen.

    Drug: MWX205

  • Placebo comparator
    Placebo

    Administration: subcutaneous injection, recommended in the abdomen.

    Drug: Placebo

Interventions

  • DrugMWX205

    Each vial contains 200mg of MWX205 small nucleic acid, with water for injection as the solvent. The excipient, including sodium hydroxide and/or hydrochloric acid, may be added to adjust the pH to 6.5±0.2.

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Incidence of TEAEs

    Time frame: From Day 1 to Day 86

  2. Incidence of SAEs

    Time frame: From Day 1 to Day 86

  3. Number of participants with abnormal vital signs

    Vital signs include tympanic body temperature, systolic and diastolic blood pressure, pulse rate, and respiratory rate

    Time frame: From Day 1 to Day 86

  4. Number of participants with abnormal Physical examination findings

    Complete physical examinations include general appearance, mouth/dental (if required), neck (including thyroid \& nodes), cardiovascular, respiratory, gastrointestinal, renal, neurological, musculoskeletal, skin, other

    Time frame: From Day 1 to Day 337

  5. Number of participants with abnormal ECG readings

    12 Lead ECG: Triplicate readings to be taken within 2 to 5 minutes of each other. ECGs are to be taken after the participant has rested in the supine position for ≥ 5 minutes

    Time frame: From Day 1 to Day 337

Secondary outcomes

  1. Plasma PK parameters Cmax (Maximum observed plasma drug concentration directly determined from the plasma concentration-time profiles)

    Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software

    Time frame: Day 1, Day 2, Day 3

  2. Plasma PK parameters- Tmax (Time to maximum observed plasma drug concentration)

    Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software

    Time frame: Day 1, Day 2, Day 3

  3. Plasma PK parameters- AUC0-inf (Area under the plasma concentration-time curve from time 0 extrapolated to infinity.)

    Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software

    Time frame: Day 1, Day 2, Day 3

  4. Plasma PK parameters- AUC0-last (Area under the plasma concentration-time curve, from time zero to the last time point with measurable analyte concentration)

    Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software

    Time frame: Day 1, Day 2, Day 3

  5. Urine PK parameters- Fe (dose fraction of the drug in its original form excreted in urine after administration)

    Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software

    Time frame: Day 1, Day 2, Day 3

  6. Urine PK parameters- Ae (cumulative excretion of the drug's original form in urine)

    Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software

    Time frame: Day 1, Day 2, Day 3

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Oct 2026, 4 months later.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 4 months is above that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jun 8, 2026
StartEst.
Jun 22, 2026
Primary completionEst.
Oct 26, 2026
CompletionEst.
Nov 8, 2027
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07634510
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
Jun 22, 2026 (estimated)
Primary completion
Oct 26, 2026 (estimated)
Completion
Nov 8, 2027 (estimated)
Last update
Jun 10, 2026

Study contacts

Mohd Naguib bin Mohd Yunos, Dr.
Contact
naguibyunos@veritusresearch.com
+61 0387361750
Mohd Naguib bin Mohd Yunos, Dr.
principal investigator · Veritus Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion